Last reviewed · How we verify
hypogammaglobulinemia
Approved treatments
- Xolremdi · X4 Pharms
Xolremdi blocks the CXC Chemokine Receptor 4 to treat WHIM syndrome.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- hypogammaglobulinemia patent landscape — cliff calendar, originator estates, attackable patents
- hypogammaglobulinemia treatment landscape brief
- hypogammaglobulinemia treatment updates RSS
Frequently asked questions about hypogammaglobulinemia
What drugs treat hypogammaglobulinemia?
Tracked treatments include Xolremdi.
What is the treatment for hypogammaglobulinemia?
Standard treatment for hypogammaglobulinemia includes Xolremdi. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: hypogammaglobulinemia patent cliff · hypogammaglobulinemia CI report
- Treatment: Xolremdi · X4 Pharms
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing